Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

Bristol Myers Squibb (NYSE:BMY) announced Saturday that its checkpoint inhibitors Opdivo and Yervoy, when combined, reduced the risk of disease progression or death by 38% in a Phase 3 trial for ...

Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) benefit when Opdivo (nivolumab ... any action on the basis of the ...

The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant overall survival benefits.

Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer ... with a target action date of April 21. Write to Colin Kellaher at colin.kellaher@ ...

Bristol Myers Squibb has won Food and Drug Administration priority review for its application seeking approval of the combination of its Opdivo and ... has set a target action date of June 23 ...

The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab ... or refraining from, any action on the basis of the content on our site.

The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.

Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer ... with a target action date of April 21.